ImmunityBio
$10.29Change from previous close: +10.83%Absolute change: +$1.01
At a glance
- Revenue growth
- +668.31%
- 2025 vs 2024
- Net margin
- -310.2%
- 2024: -2,804.8%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 113 | 14.7 | 0.6 | 0.2 | — |
| Cost of revenue | 0.8 | 0.0 | 0.0 | 0.0 | — |
| Gross profit | 113 | 14.7 | 0.6 | 0.2 | — |
| Selling, general and administrative | 150 | 169 | 130 | 103 | — |
| Research and development | 219 | 190 | 232 | 248 | — |
| Operating income | -256 | -344 | -361 | -351 | — |
| EBIT | -239 | -282 | -497 | -370 | — |
| EBITDA | -224 | -264 | -479 | -352 | — |
| Interest expense | 113 | 132 | 86.8 | 47.1 | — |
| Pre-tax income | -352 | -414 | -584 | -417 | — |
| Income tax | -0.1 | 0.0 | -0.0 | 0.0 | — |
| Net income | -351 | -414 | -583 | -417 | — |
| Net income to common shareholders | -351 | -414 | -583 | -417 | — |
| Basic EPS | -0.38 | -0.59 | -1.15 | -1.04 | — |
| Diluted EPS | -0.38 | -0.62 | -1.15 | -1.04 | — |
| Average shares (basic) | 920 | 697 | 509 | 400 | — |
| Average shares (diluted) | 920 | 700 | 509 | 400 | — |